NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Category: FDA

9/13/2017

Worrisome ‘right to try’ legislation may soon become law. Here’s the story that some news outlets missed

8/29/2017

FDA announces action against two stem cell clinics: Is that a ‘crackdown’?    

2 7/11/2017

Fact-checking pharma: 5 cancer drug myths, busted

1 1/26/2017

Approval of ‘breakthrough’ hepatitis C drugs isn’t even half the story; now come the harms

1/9/2017

Whitewashing a black box warning: The Chantix story that didn’t get told

11 12/6/2016

With media watchdogs on the sidelines, pharma-funded advocacy groups pushed Cures Act to the finish line  

1 11/29/2016

Off-label drug marketing: Who will decide what’s “truthful” when the evidence can’t be trusted?   

10/31/2016

Early report card on quality of FDA news releases: C at best

10/25/2016

Black box warnings for ‘lifesaving’ hepatitis C drugs highlight systematic misinformation

3 9/28/2016

What some stories missed about the muscular dystrophy drug approval: Pharma’s close ties to vocal patient advocacy groups